Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019
Description
Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti-cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999, it was approved to treat advanced gastric cancer and then such indications as head and neck neoplasm, inoperable or unresectable breast cancer, non-small cell carcinoma, colon cancer, pancreatic cancer and bile duct cancer.
Years of clinical application prove that tegafur, gimeracil and oteracil is a safe and effective anti-cancer drug. According to statistics, over 80% of advanced gastric cancer patients use tegafur, gimeracil and oteracil in chemotherapy, CR + PR reaching 44.6%.
According to CRI’s statistics, tegafur, gimeracil and oteracil develops fast after entering China with annual sales rising from less than CNY 20 million in 2009 to CNY 707 million in 2014 and CAGR reaching up to 110% during the period of 2009-2014, which demonstrats a bright future. Tegafur, gimeracil and oteracil enjoys a vast demand in China. Currently, tegafur, gimeracil and oteracil in the Chinese market come from the following four companies: Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation, Qilu Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd and Jiangsu Hengrui Medicine Co., Ltd, among which Shandong New Time Pharmaceutical Co., Ltd has the largest market share of nearly 50% with sales reaching up to CNY 348 million in 2014.
The market size of tegafur, gimeracil and oteracil in China is expected to keep growing.
Readers can get at least the following information through this report:
Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti-cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999, it was approved to treat advanced gastric cancer and then such indications as head and neck neoplasm, inoperable or unresectable breast cancer, non-small cell carcinoma, colon cancer, pancreatic cancer and bile duct cancer.
Years of clinical application prove that tegafur, gimeracil and oteracil is a safe and effective anti-cancer drug. According to statistics, over 80% of advanced gastric cancer patients use tegafur, gimeracil and oteracil in chemotherapy, CR + PR reaching 44.6%.
According to CRI’s statistics, tegafur, gimeracil and oteracil develops fast after entering China with annual sales rising from less than CNY 20 million in 2009 to CNY 707 million in 2014 and CAGR reaching up to 110% during the period of 2009-2014, which demonstrats a bright future. Tegafur, gimeracil and oteracil enjoys a vast demand in China. Currently, tegafur, gimeracil and oteracil in the Chinese market come from the following four companies: Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation, Qilu Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd and Jiangsu Hengrui Medicine Co., Ltd, among which Shandong New Time Pharmaceutical Co., Ltd has the largest market share of nearly 50% with sales reaching up to CNY 348 million in 2014.
The market size of tegafur, gimeracil and oteracil in China is expected to keep growing.
Readers can get at least the following information through this report:
- market share of manufacturers of tegafur, gimeracil and oteracil in Chinese market
- price of tegafur, gimeracil and oteracil in Chinese market
- major manufacturers of tegafur, gimeracil and oteracil in China
- share of different dosage forms of tegafur, gimeracil and oteracil in Chinese market
- market outlook of tegafur, gimeracil and oteracil in China
- manufacturers of antitumor drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF TEGAFUR, GIMERACIL AND OTERACIL
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA
2.1 Patent and Approval Status of Tegafur, Gimeracil and Oteracil in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURES OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINESE HOSPITALS IN 2014
6.1 Qilu Pharmaceutical Co., Ltd
6.2 Taiho Pharmaceutical Co., Ltd
6.3 Jiangsu Hengrui Medicine Co., Ltd
6.4 Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
7 MAJOR MANUFACTURERS OF TEGAFUR, GIMERACIL AND OTERACIL IN THE CHINESE MARKET, 2010-2014
7.1 Qilu Pharmaceutical Co., Ltd
7.2 Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
7.3 Jiangsu Hengrui Medicine Co., Ltd
7.4 Taiho Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA
2.1 Patent and Approval Status of Tegafur, Gimeracil and Oteracil in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURES OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINESE HOSPITALS IN 2014
6.1 Qilu Pharmaceutical Co., Ltd
6.2 Taiho Pharmaceutical Co., Ltd
6.3 Jiangsu Hengrui Medicine Co., Ltd
6.4 Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
7 MAJOR MANUFACTURERS OF TEGAFUR, GIMERACIL AND OTERACIL IN THE CHINESE MARKET, 2010-2014
7.1 Qilu Pharmaceutical Co., Ltd
7.2 Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
7.3 Jiangsu Hengrui Medicine Co., Ltd
7.4 Taiho Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF TEGAFUR, GIMERACIL AND OTERACIL IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
SELECTED CHARTS
Chart Approval Information of Tegafur, Gimeracil and Oteracil in China
Chart Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Sales Value of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Sales Value of Tegafur, Gimeracil and Oteracil in Some Regions in China, 2010-2014
Chart Sales Volume of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Market Share of TOP4 Manufacturers of Tegafur, Gimeracil and Oteracil by Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Taiho (Japan) in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Shandong New Time in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Capsules in China, 2010-2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Taiho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Jiangsu Aosaikang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Approval Information of Tegafur, Gimeracil and Oteracil in China
Chart Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Sales Value of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Sales Value of Tegafur, Gimeracil and Oteracil in Some Regions in China, 2010-2014
Chart Sales Volume of Tegafur, Gimeracil and Oteracil in China, 2010-2014
Chart Market Share of TOP4 Manufacturers of Tegafur, Gimeracil and Oteracil by Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Taiho (Japan) in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Shandong New Time in China, 2010-2014
Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Capsules in China, 2010-2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Taiho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tegafur, Gimeracil and Oteracil Made by Jiangsu Aosaikang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
